Navigation Links
Taking the needle's sting out of diabetes
Date:8/10/2009

Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, new research published in the June issue of the European Journal of Pharmacology shows that the drug might be able to slow the progression of diabetes as well.

Prof. Kloog's student Adi Mor of TAU's Department of Neuro-biochemistry and Sackler School of Medicine has modified Prof. Kloog's anti-Ras FTS compound to develop what could be the first tablet-based treatment for children and adults with Type 1 diabetes. Early results show that FTS is effective in restoring insulin production in animal models ― which could spell an end to the daily needle injections endured by diabetics.

"Our anti-Ras compound has shown very positive results in inhibiting diabetes," says Mor. And given the drug's history FTS has already passed toxicity studies for other diseases and disorders it has the potential to fast-track through FDA regulatory hurdles, skipping straight to Phase II clinical trials. A new drug for diabetes could be ready in as little as five years' time.

Helping the immune system do its job

Previous studies by Prof. Kloog's lab found that the FTS compound is effective against autoimmune diseases such as multiple sclerosis and lupus, "but the mechanism of its effects on immune cells was not well understood," says Mor. "I wanted to see if there was a connection between Ras and the regulation of the immune system, and if so if FTS could help regulate it to prevent or slow diabetes."

Through treating cells with the Tel Aviv University FTS compound, Mor was able to find and isolate an important immune system regulator protein called Foxp3. This protein keeps T cells in the immune system in check. T cells are the immune system's "soldiers" that fight off infection and disease. In her studies in the lab, when Mor blocked Ras using the FTS drug, she was able to increase the Foxp3 protein which gave a boost to the all-important T cells.

Slowing diabetes to a crawl

Mor then theorized that if the amount of regulatory T cells in the body was increased, the progression of diabetes would diminish. "My aim was to slow down diabetes, which brings a suitcase of side-effects like circulatory problems that lead to blindness and amputations," she says.

In her recent study, Mor treated pre-diabetic mice for six months. One group was given FTS, another was given no drug at all. The outcome was dramatic. Only 16% of the treated group developed diabetes, while 82% of the untreated group became diabetic. Also, insulin production from beta cells in the treated group of mice increased in comparison to insulin production in the non-treated group, she reports.

"Diabetes is my main concern," Mor concludes. "So many children and adults continue to suffer from the disorder. Since the FTS molecule is very easily absorbed into the blood, it could be the first diabetes treatment in pill form to moderate insulin production in juvenile diabetes, slowing down the progression of the disease. It could help a lot of people."


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Mathematics taking guesswork out of plastic surgery tissue transfer
2. Looking to Shape Up for Summer? The Solution May Be the Steps Youre Already Taking
3. Swine Flu Vaccine Taking Longer Than Expected
4. Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin
5. Looking to Shape up for Summer? The Solution May be the Steps Youre Already Taking
6. Taking Aim at Relapse of Leukemia in Kids
7. Value of Taking Aspirin to Cut Heart Risk Varies
8. Financial Distress Taking Toll on Employee Health
9. Taking a Bite Out of Rabies: Merial Provides Rabies Awareness and Prevention Training to Noahs Wish Pet Disaster Relief Organization
10. Chronic diarrhea unresponsive to conventional medication: Are you taking lansoprazole?
11. Taking folic acid for a year before pregnancy may reduce risk of preterm birth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Taking the needle's sting out of diabetes
(Date:1/23/2017)... , ... January 23, 2017 , ... ... Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 ... panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature an ...
(Date:1/23/2017)... , ... January 23, 2017 , ... "ProRandom is a set of camera tools that ... dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... two layers of text with video footage. ProRandom works by using a virtual camera ...
(Date:1/23/2017)... ... ... the Mill”: a story of love and redemption, hope and uncertainty as a girl ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, who ... living in Berks County on Crow Hill. The inn, the mill and "Post ...
(Date:1/23/2017)... ... ... Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts and ... author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was a ... pastor for over fifteen years. He is a graduate of N.C. College of Theology ...
(Date:1/22/2017)... ... ... "Photo Cloud allows FCPX users to add favorited photos to any drop ... Christina Austin - CEO of Pixel Film Studios. , To begin, select a ... include scenes with one, three, four or five focus points. There are five included ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive ... NeuroVive has signed a preclinical collaboration agreement with the Children,s ... Marni J. Falk , M.D., a US key opinion leader ... ... CHOP will evaluate compounds from NeuroVive,s research program, NVP015, in ...
(Date:1/23/2017)... LONDON , Jan. 23, 2017 Just two weeks remain ... and intellectual property, gather in Central London to ... of its kind in the market, Parallel Trade 2017 . ... a preliminary list of attendees which is available to read in the ... ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
Breaking Medicine Technology: